StopDown

PharmEasy vs Tata 1mg: revenue, valuation and funding compared

The short answer

PharmEasy reported the highest revenue, ₹6,618.5 crore in FY26, against Tata 1mg ₹2,936 crore in FY26. PharmEasy and Tata 1mg reported a loss.

PharmEasy and Tata 1mg are two of the widely known online pharmacies in India, so shoppers and investors often set them side by side. Both sell medicines, supplements and diagnostics through an app. PharmEasy is a Mumbai company founded in 2015 and run by API Holdings, which also owns the diagnostics firm Thyrocare. Tata 1mg is a unit of Tata Digital, which took a majority stake in it in June 2021.

The table shows FY26 for both, with FY24 for PharmEasy and FY25 and FY24 for Tata 1mg. PharmEasy's figures are those of its parent, API Holdings, so they include Thyrocare and the B2B businesses. Tata 1mg's are consolidated across its two entities. Every number on this page comes from the companies' StopDown profiles.

Side by side

PharmEasy vs Tata 1mg: latest reported figures, ₹ crore unless stated, financial year in each cell
PharmEasyTata 1mg
Founded2015—
Based inMumbai—
What it sellsOnline pharmacy, lab tests and doctor consults, run by API HoldingsOnline pharmacy and diagnostics platform run by Tata Digital
StatusPrivateTata Digital unit
Revenue, latest year₹6,618.5 crore FY26 Bigger₹2,936 crore FY26
Revenue, year before₹5,664.2 crore FY24₹2,392 crore FY25
Growth—+23% (FY25 to FY26)
Net profit (loss), latest year₹520 crore loss FY26₹287 crore loss FY26
Last disclosed valuation——
Total raised——
Last roundDebentures (debt), ₹1,700 crore (about $193 million), Sep 2025—
ProfilePharmEasy on StopDownTata 1mg on StopDown

Scale

PharmEasy's parent is the bigger business by a wide margin. API Holdings reported revenue from operations of ₹6,618.5 crore in FY26, up 12.7%. Tata 1mg reported ₹2,936 crore in FY26, up 23% from ₹2,392 crore in FY25. So Tata 1mg grew faster, but from a much smaller base.

The gap is partly a matter of scope. PharmEasy's number covers a group with a listed diagnostics arm, while Tata 1mg's covers the pharmacy and technology units. Within Tata 1mg, Healthcare Solutions brought ₹2,440 crore and Technologies brought ₹496 crore. For an earlier year, PharmEasy's parent reported ₹5,664.2 crore in FY24, against ₹1,968 crore for Tata 1mg. Both numbers are consolidated group figures, so neither is a standalone pharmacy figure, and this is most clearly read as group against group. PharmEasy's parent also owns the B2B businesses Ascent and Aknamed, which Tata 1mg has no equivalent of in its profile.

Money

Both are loss-making. API Holdings reported a consolidated net loss of ₹520 crore in FY26, down 67% from a year earlier. In FY24 its loss was ₹2,531 crore. Tata 1mg's net loss was ₹287 crore in FY26, after ₹276 crore in FY25 and ₹313 crore in FY24.

The two losses have different shapes. At Tata 1mg, Healthcare Solutions lost ₹310 crore while Technologies made a profit of ₹23 crore. At PharmEasy's parent, the profile does not break the loss down by business. In August 2026 API Holdings cleared a ₹1,050 crore term loan with proceeds from selling about 9.90% of Thyrocare and some internal cash. On the cost side, PharmEasy's parent reported expenses of ₹7,146.7 crore in FY26 against revenue of ₹6,618.5 crore, which is how the loss arises. Tata 1mg's expenses were ₹2,682 crore in FY25 against revenue of ₹2,392 crore.

Where they are heading

PharmEasy's management is aiming for profit outside Thyrocare by September 2027. It says it could still list, or merge with Thyrocare, later, according to Moneycontrol. It planned an IPO to raise ₹6,250 crore in 2021, which was later withdrawn because of market volatility. In March 2026 it launched a WomenCare category.

Tata 1mg's profile lists no announced plans beyond its FY26 results. It names Netmeds, PharmEasy and Apollo 24/7 as rivals. Tata 1mg is a unit of Tata Digital rather than a standalone company, so any decision on its future sits with the group. In September 2025 API Holdings also raised ₹1,700 crore through debentures to redeem earlier debentures, and after the August 2026 sale it still holds 51.02% of Thyrocare. PharmEasy's chief executive is Rahul Guha.

The numbers behind the table

PharmEasy: revenue and profit by year

PharmEasy revenue and profit by financial year, ₹ crore, from filings and statements as reported
YearRevenueProfit or lossNote
FY26₹6,618.5 crore₹520 crore lossAPI Holdings (parent of PharmEasy), consolidated; revenue from operations, up 12.7%; total income ₹6,689.2 crore; FY25 left out because sources differ on its revenue and loss
FY24₹5,664.2 crore₹2,531 crore lossAPI Holdings (parent of PharmEasy), consolidated; operating revenue, as shown with the FY25 results

Tata 1mg: revenue and profit by year

Tata 1mg revenue and profit by financial year, ₹ crore, from filings and statements as reported
YearRevenueProfit or lossNote
FY26₹2,936 crore₹287 crore lossconsolidated, the two Tata 1mg entities combined, as reported by Entrackr from filings; Tata Digital unit, not a standalone company
FY25₹2,392 crore₹276 crore lossconsolidated, both Tata 1mg entities combined, from Tata Sons' annual report as read by Entrackr; FY25 profit before tax of ₹290 crore in the same article is not reconciled with the loss and is left out
FY24₹1,968 crore₹313 crore lossconsolidated, as reported by Entrackr from Tata Sons' annual report

PharmEasy: funding rounds

PharmEasy funding rounds, as announced
DateRoundAmountInvestors
Sep 2025Debentures (debt)₹1,700 crore (about $193 million)Lenders not named in the report
2024Fundraise (equity)₹800 crore from Ranjan Pai's family officeRanjan Pai's family office
2023Rights issue (equity)₹1,300 crore from Ranjan PaiRanjan Pai, chairman of Manipal Group
2022Debentures (debt)$300 million (₹2,220 crore)Goldman Sachs

Questions people ask

Which is bigger, PharmEasy or Tata 1mg?

PharmEasy's parent. API Holdings reported revenue from operations of ₹6,618.5 crore in FY26, against ₹2,936 crore for Tata 1mg. The PharmEasy figure covers the whole group, including Thyrocare.

Is PharmEasy profitable?

No. API Holdings reported a consolidated net loss of ₹520 crore in FY26, down 67% from a year earlier. Management is aiming for profit outside Thyrocare by September 2027. Tata 1mg also made a loss, of ₹287 crore in FY26.

Who owns Tata 1mg?

Tata Digital owns Tata 1mg as a group unit. It took a majority stake in June 2021. PharmEasy belongs to API Holdings, whose backers include TPG, Prosus Ventures, Temasek, CDPQ and Eight Roads.

Which raised more?

PharmEasy. Its profile lists ₹2,220 crore of debentures from Goldman Sachs in 2022, ₹1,300 crore from Ranjan Pai in 2023, ₹800 crore in 2024 and ₹1,700 crore of debentures in September 2025. Tata 1mg's profile lists no funding rounds.

Every figure on this page comes from the companies' StopDown profiles, which list the filing or statement behind each number: PharmEasy, Tata 1mg. Revenue is revenue from operations unless the note says otherwise; valuations are as disclosed at a round or by the company; nothing here is investment advice. How StopDown counts.